Scancell’s first cancer vaccine SCIB1 is being developed for thetreatment of melanoma and will enter clinical trials in early 2010.Treating cancer by vaccination allows small non-toxic doses of a vaccine to beadministered to a patient, stimulating an immune response. Effective cancervaccines need to target dendritic cells to stimulate both parts of the cellularimmune system; the helper cell system where inflammation is stimulated at thetumour site; and the cytotoxic T-lymphocyte or CTL response where immune systemcells are primed to recognise and kill specific cells.A limitation of many cancer vaccines currently in development is that theycannot specifically target dendritic cells in vivo. Theagreement will add further strength to Scancell’s IP position, as it continuesto progress its development of therapeutic vaccines based on the Immunobody®platform.”The Directors of the issuer accept responsibility for this announcement.-ENDS- For Further Information:Professor Lindy Durrant Scancell Holdings Plc+ 44 207 245 1100Adam Reynolds/Vikki KrauseHansard Group+ 44 7515 922906 Ross AndrewsZeus Capital + 44 (0)161 831 1512About ScancellScancell is developing novel therapeutic vaccines for the treatment of cancerand infectious diseases based on its groundbreaking ImmunoBody® technologyplatform. If you are in any doubt as to whether or not you are requiredto disclose a “dealing” under Rule 8, you should consult the Panel.Collins Stewart, which is authorised and regulated by the Financial ServicesAuthority, is acting for the Company and for no one else in connection with thematters detailed in this announcement and will not be responsible to anyoneother than the Company for providing the protections afforded to clients ofCollins Stewart or for affording advice in relation hereto, or any othermatters referred to herein.END. 02/07/2009 GB00B39J5N63 Scancell Holdings Plc (`Scancell Holdings’ or the `Company’) Scancell licenses key ImmunoBody® patents from Merck SeronoScancell Holdings Plc, the parent company of Scancell Limited (`Scancell’), thedeveloper of therapeutic cancer vaccines based on its patented ImmunoBody®platform, is pleased to announce it has signed a licensing agreement with MerckKGaA, Darmstadt, Germany, acting for its division Merck Serono, for two keypatents required for the further development and commercialisation of proteinImmunoBody® vaccines. In particular, a person will be treated as having an “interest” byvirtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.Terms in quotation marks are defined in the Code, which can also be found onthe Panel’s website.

The ISIN number for the Shares is GB00B063C843.Dealing Disclosure RequirementsUnder the provisions of Rule 8.3 of the Code, if any person is, or becomes,”interested” (directly or indirectly) in 1% or more of any class of “relevantsecurities” of the Company, all “dealings” in any “relevant securities” of thatcompany (including by means of an option in respect of, or a derivativereferenced to, any such “relevant securities”) must be publicly disclosed by nolater than 3.30 pm (London time) on the London business day following the dateof the relevant transaction. It should be noted that cash included above may be usedto fund any required cash flows from foreign exchange hedging as well as othercosts arising in the ordinary course.Contacts for queries:Tapestry Investment Company PCC LimitedMel Carvill (Chairman)01481 727111Jeremy Ozanne (Company secretary)01481 752495Collins Stewart Europe LimitedAndrew Zychowski020 7523 8363Pursuant to Rule 2.10 of the Takeover Code (the “Code”), the Company currentlyhas an issued share capital of 90,594,850 redeemable participating preferenceshares (the “Shares”) of no par value, of which 6,618,010 are now held intreasury. Assets listed under `Uncertain Payout Timing’ representthose investments held by the Company where the underlying hedge fund hassuspended redemptions, created side pockets or where the fund is inliquidation.There may be other matters or factors which affect the availability, amount ortiming of receipt of the proceeds of realisation of some or all of theCompany’s investments. Any offer is expected to have the customary acceptance conditionof 90% of shares to which the offer relates, however, the level of acceptancesrequired under this condition may be reduced, at the Investment Managers’ solediscretion. The consideration of any offer would be aformula offer, calculated by reference to the net asset value of the Company,with a potential additional deferred consideration payment equal to 50% of theuplift in the value of the Company’s portfolio in US dollar terms afterexpenses, from the date that any offer goes unconditional as to acceptances to31 March 2010. publication of non-statutory accounts The above does not constitute statutory accounts within the meaning of section434 of the Companies Act 2006.

It is an extract from the full accounts for theyear ended 30 April 2009 on which the auditor has expressed an unqualifiedopinion. The accounts will be posted to shareholders and subsequently filed atCompanies House.END. TAPESTRY INVESTMENT COMPANY PCC LIMITED (the “Company”)2 July 2009Potential Offer and updated Liquidity Schedule Potential OfferIn the course of the board of directors’ (the “Board”) deliberations aboutappropriate options to enable the Company’s shareholders to realise theirinvestments as announced on 30 April 2009, the Board has received an approachfrom the Company’s investment manager, Ramius (the “Investment Manager”), whichmay lead to a cash offer for the entire issued share capital of the Companybeing made.In present market conditions the Investment Manager has indicated that an offercould be made at a discount of 15.4% to net asset value at the time the offergoes unconditional as to acceptances. Loss per ordinary share The calculation of the basic earnings per share is based on the lossattributable to ordinary shareholders divided by the weighted average number ofshares in issue during the year.